发明名称 MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA WITHOUT CO-ADMINISTRATION OF LITHIUM
摘要 The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. The present invention also relates to the use of the microporous zirconium silicate compositions in the treatment of diseases, where the subject is not concurrently receiving lithium based drugs. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
申请公布号 US2015313938(A1) 申请公布日期 2015.11.05
申请号 US201414565965 申请日期 2014.12.10
申请人 ZS Pharma, Inc. 发明人 KEYSER Donald Jeffrey;GUILLEM Alvaro F.
分类号 A61K33/24 主分类号 A61K33/24
代理机构 代理人
主权项 1. A method for treating hyperkalemia comprising administering to a subject in need thereof a composition comprising a zirconium silicate of formula (I): ApMxZr1-xSinGeyOm  (I)where A is a potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof, M is at least one framework metal, wherein the framework metal is hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), terbium (4+) or mixtures thereof, “p” has a value from about 1 to about 20, “x” has a value from 0 to less than 1, “n” has a value from about 1 to about 12, “y” has a value from 0 to about 12, “m” has a value from about 3 to about 36 and 1≦n+y≦12, wherein the composition exhibits a median particle size of greater than 3 microns and less than 7% of the particles in the composition have a diameter less than 3 microns, and the composition exhibits a sodium content below 12% by weight, and wherein the subject is not concurrently receiving other alkali earth based drugs.
地址 Coppell TX US